Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$21.10 USD

21.10
1,979,088

-0.03 (-0.14%)

Updated Sep 16, 2025 03:59 PM ET

After-Market: $21.50 +0.40 (1.90%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ISRG Stock Dips Despite Introducing Real-Time Insights on da Vinci 5

by Zacks Equity Research

Intuitive Surgical unveils real-time surgical insights on its da Vinci 5, enhancing precision, safety, and efficiency with advanced software features.

Zacks Equity Research

GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio

by Zacks Equity Research

GE HealthCare moves to strengthen its neurology portfolio by acquiring icometrix, aiming to integrate AI-driven brain MRI solutions into its imaging platforms.

Zacks Equity Research

MMSI Stock Falls Despite CE Mark Win for Embosphere in Knee OA Care

by Zacks Equity Research

Merit Medical secures CE Mark for Embosphere, expanding its use in knee osteoarthritis treatment with a minimally invasive alternative.

Zacks Equity Research

QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio

by Zacks Equity Research

QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.

Zacks Equity Research

Why Envista (NVST) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs

by Zacks Equity Research

EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.

Zacks Equity Research

Should You Add IDEXX Stock to Your Portfolio Right Now?

by Zacks Equity Research

IDXX shows strong CAG Diagnostics growth, cloud software momentum and global expansion but faces solvency and macro risks.

Zacks Equity Research

CRL Stock Rises Following New Strategic Oncology Collaborations

by Zacks Equity Research

Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.

Zacks Equity Research

Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study

by Zacks Equity Research

PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.

Zacks Equity Research

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

by Zacks Equity Research

OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.

Zacks Equity Research

Here's Why You Should Add NVST Stock to Your Portfolio Right Now

by Zacks Equity Research

Envista's global expansion, strategic acquisitions, and solid solvency boost growth outlook despite FX headwinds.

Zacks Equity Research

Encompass Health Opens New Rehabilitation Hospital in The Villages

by Zacks Equity Research

EHC expands in Central Florida with a new 50-bed rehab hospital in The Villages, boosting its growth and patient care network.

Zacks Equity Research

NVST vs. ABT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NVST vs. ABT: Which Stock Is the Better Value Option?

Zacks Equity Research

Should You Continue to Hold EXAS Stock in Your Portfolio?

by Zacks Equity Research

Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.

Zacks Equity Research

Here's Why You Should Add PAHC Stock to Your Portfolio Right Now

by Zacks Equity Research

Phibro Animal Health posts strong Animal Health sales growth, aided by a Zoetis acquisition, while Mineral Nutrition and Performance Products rebound.

Zacks Equity Research

Dentsply Sirona Retains Wellspect Following Strategic Review

by Zacks Equity Research

XRAY will keep its Wellspect unit, betting on its strong cash flows and $2B market to deliver greater long-term shareholder value.

Zacks Equity Research

Best Value Stocks to Buy for September 10th

by Zacks Equity Research

CZFS, SRCE and NVST made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 10, 2025.

Zacks Equity Research

Lifeward Achieves European Approval for Latest ReWalk Exoskeleton

by Zacks Equity Research

LFWD secures CE mark for its ReWalk 7 Personal Exoskeleton, unlocking new European sales potential with advanced features.

Zacks Equity Research

ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay

by Zacks Equity Research

The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.

Zacks Equity Research

MYGN Stock Might Gain on The Lancet Study Backing Precise MRD

by Zacks Equity Research

Myriad Genetics' Precise MRD study in The Lancet shows ctDNA detection power in oligometastatic ccRCC, supporting oncology growth plans.

Zacks Equity Research

MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?

by Zacks Equity Research

Myriad Genetics' GeneSight test outperforms treatment-as-usual in major depression, raising hopes for broader adoption and renewed stock momentum.

Zacks Equity Research

MDT Stock May Benefit From New Regulatory Wins for Its MiniMed 780G

by Zacks Equity Research

Medtronic secures FDA milestones for its MiniMed 780G system, expanding use to type 2 diabetes and enabling sensor integration.

Zacks Equity Research

Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?

by Zacks Equity Research

GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.

Zacks Equity Research

Is it the Right Time to Add CRL Stock to Your Portfolio Now?

by Zacks Equity Research

Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.

Zacks Equity Research

QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise

by Zacks Equity Research

QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.